Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Read the original here:
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
See the article here:
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators
Go here to read the rest:
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
Findings from recently completed Rheumatoid Arthritis Study raise questions Findings from recently completed Rheumatoid Arthritis Study raise questions
More here:
XBiotech Pauses Rheumatology program
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
Read more:
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the 100th commercial RhodoLED® XL Lamp has now been installed in the US market.
View post:
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
MINNEAPOLIS, MN, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its 2024 Annual General Meeting of its Shareholders at 9:30 am CST on Tuesday, December 31, 2024.
The rest is here:
FOXO TECHNOLOGIES INC. ANOUNCES DETAILS OF ITS 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2024
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website.
View original post here:
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
HALIFAX, Nova Scotia and SPRING, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Scientists at Dalhousie University in Halifax, and Io Therapeutics, Inc. in Spring Texas, announced today collaborative publication of data from studies demonstrating effectiveness of the RXR agonist compound IRX4204 in reversing demyelination, and functionally restoring movement in the paralyzed legs of mice subjected to an autoimmune-mediated demyelinating model of human multiple sclerosis (MS). The research report titled: “Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis”, G.D.S Kasheke, et al; was published in the December 21, 2024 edition of Acta Neuropathologica Communications.
Read the original:
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis